FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

The U.S. Food and Drug Administration (FDA) has approved Bristol-Myers Squibb’s (BMS) NS5A inhibitor Daklinza (daclatasvir) to be used in combination with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C. This is the first hep C regimen ever to be specifically approved for genotype 3, and it improves cure rates over other currently available treatments. However, the cure rate anticipated for those with cirrhosis is still quite poor.

Twelve weeks of once-daily regimen is recommended.

An estimated 12 percent of Americans with hep C are infected with genotype 3. It is the second most common genotype in the United States, behind genotype 1, which makes up about 70 percent of the U.S. epidemic. Read more....